小木虫 --- 600万学术达人喜爱的学术科研平台
&&查看话题
帮忙翻译一下呢！
Lung Cancer Vaccine Enters Large-scale Clinical Trial
A new treatment for the most common form of lung cancer, developed from initial research by Cancer Research UK entists, has entered a pivotal phase III clinical trial.
The drug, called Stimuvax, is a type of therapeutic vaccine that targets a specific protein found in many tumours, including non-small cell lung cancer. It was developed by Canadian biotech company Biomira following Cancer Research UK-funded studies led by Professor Joyce Taylor-Papadimitriou of Guy's Hospital, London. Biomira have already run phase II trials with very encouraging results.
The international phase III trial, named START (Stimulating Targeted Antigenic Responses To NSCLC), is expected to enrol its first patient this month. Run by pharmaceutical company Merck KGaA, it will eventually include more than 1,300 lung cancer patients in 30 countries, including the UK.
Therapeutic vaccines are a relatively new development in cancer treatment. Unlike preventative vaccines, they are treatments that induce the body's own immune system to identify and kill existing cancer cells. Stimuvax is designed to stimulate the immune system to recognise and react to a molecule called MUC1, which is much more abundant on tumour cells than healthy cells. The immune system then kills the cancer cells with MUC1, hopefully without overly harming healthy cells.
Cancer Research Technology Limited (CRT), Cancer Research UK's development and commercialisation company, licensed a number of discoveries to Biomira, which led to the development of Stimuvax for advanced non small cell lung cancer. Merck KGaA also plans to investigate the use of Stimuvax for other types of cancer.
Dr Keith Blundy, chief operating officer of CRT, said: "We are extremely pleased that Stimuvax has entered the final stage of clinical trials. The drug is one of CRT's portfolio of more than 20 partnered agents in clinical development. Targeted vaccines are an exciting approach that could potentially offer new treatment options for major types of cancer."
Harpal Kumar, chief executive of CRT and chief operating officer of Cancer Research UK, said: "We're delighted that another drug based on Cancer Research UK-funded basic research has reached the final stage of clinical development. The 'translation' of basic research into patient benefit is the major focus of our work and we hope that new ventures, such as the expansion of our drug discovery activities across the country, will lead to many more such drugs entering trials in the future."
Lung cancer
-- Lung cancer is the second most common cancer in the UK after breast cancer, and the most common cancer worldwide.
-- There were more than 37,000 cases of lung cancer diagnosed in the UK in 2003.
-- Non small cell lung cancer accounts for 80 per cent of total lung cancer cases.
-- Current standard treatments for lung cancer patients are surgery, platinum-based combination chemotherapy and radiotherapy.
START trial
In the trials, Stimuvax will be compared to a placebo. More information on the START trial can be found here.
Research centres in Edinburgh, Leeds and Exeter will be participating in the trial.
For more information about clinical trials in the UK, visit Cancer Research UK's patient information website, CancerHelp UK.
Cancer Research Technology
Cancer Research Technology Limited (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. Further information about CRT can be found here.
About Cancer Research UK
Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
-- Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.
-- Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.
-- Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.
-- Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.
2030人参与
关于帮忙翻译一下呢！的相关话题在小木虫APP已经有171位虫友给出了详细回复。
赶快查看回复吧！
学术必备与600万学术达人在线互动！
扫描下载送金币
北京学而思教育科技有限公司 地址：北京市海淀区北三环甲18号中鼎大厦A座1层102室 电话：010-
浏览器进程
打开微信扫一扫
随时随地聊科研请那位大神帮我翻译一下下面这句话，非常感谢！（感觉怎么翻都不对）
From my perspective, she has the complete gift.
自己的思考，complete有完整、全面的意思，而gift既可以表达礼物也可以表示为馈赠或者天赋等。
所以可以翻译为：
1、在我看来，她拥有一个完美的礼物。
感觉complete翻完整的很别扭，翻为完美貌似又没有这个意思。
2、在我看来，她能力出众（天赋异禀）。
这里把gift看作为天赋，complete看为完整，全面。全面的天赋就让我想到了天赋异禀，不过还是觉得有点别扭。
请教给位大牛了，欢迎讨论，不甚感激。
**From my perspective, she has the compl...
有上文吗？猜测是
以我来看，她完全有这个天赋。
**From my perspective, she has the compl...
我看她行...
我个人认为，他很有天赋
有上文吗？猜测是以我来看，她完全有这个天赋。...
上下文好像没有呢，不过看了你翻的这个感觉顺多了，谢谢~
我看她行...
我个人认为，他很有天赋...
我一开始也是这么翻的
有上文吗？猜测是以我来看，她完全有这个天赋。...
给力！点赞
我看她行...
另一种翻译风格
我一开始也是这么翻的...
记住from my perspective 在写作中经常用来表达观点看法的
没有加入小组
**From my perspective, she has the compl...
在我看来，她就是上天的宠儿
没有加入小组
**From my perspective, she has the compl...
在我看来，她完全是个天才。
**From my perspective, she has the compl...
依我看，非她莫属。
这个帖子太久没有人回复啦，你还是开个新帖吧
Really delete this post?
您的电脑上安装了某些视频广告拦截软件，这会导致无法提交学习数据。
您可以退出相应软件后刷新网页继续学习。
大于号&或右方向键或D键
选择相应选项
数字键0到4，0为忘记
显示词根详情（需购买智慧词根应用）
显示派生词信息（需购买派生词应用）
关闭对话框帮我翻译一下！大致是什么意思！_缙云吧_百度贴吧
&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&签到排名：今日本吧第个签到，本吧因你更精彩，明天继续来努力！
本吧签到人数：0成为超级会员，使用一键签到本月漏签0次！成为超级会员，赠送8张补签卡连续签到：天&&累计签到：天超级会员单次开通12个月以上，赠送连续签到卡3张
关注：44,042贴子：
帮我翻译一下！大致是什么意思！收藏
ISSN Online: Call for PapersApplied MathematicsDear 帮我写下料优化,This e-mail is sent from Applied Mathematics (AM), a peer-reviewed open access journal. We would like to invite you to submit related papers to us via the Paper Submission System.PubMed and PubMed CentralSome papers from AM have been indexed by PubMed and PubMed Central.Volume 6, Number 11, October 2015Binary-Real Coded Genetic Algorithm Based k-Means Clustering for Unit Commitment ProblemMai A. Farag, M. A. El-Shorbagy, I. M. El-Desoky, A. A. El-Sawy, A. A. MousaChaos Synchronization in Lorenz SystemAyub Khan, Prempal SinghNew Modification of Fixed Point Iterative Method for Solving Nonlinear EquationsMuhammad Saqib, Muhammad Iqbal, Shahzad Ahmed, Shahid Ali, Tariq IsmaeelRecent Advances in Global Optimization for Combinatorial Discrete ProblemsAdel R. Awad, Samia O. ChibanSpecial Issues in AMFractal Theory and Applications (Manuscript Due: November 26th, 2015)Information Theory (Manuscript Due: December 30th, 2015)Fuzzy Mathematics and Its Applications (Manuscript Due: January 21st, 2016)&&More
不如先从她的同款手机——魅蓝E2开始聊起
最近没有时间上电脑！
不上电脑手机查也是一样的。
ISSN在线：论文征集应用数学亲爱的帮我写下料优化，此邮件是从应用数学（AM），同行评议的开放获取期刊发。我们想请您通过投稿系统提交相关的文件给我们。考研和PubMed中心从上午有些论文被收录考研和PubMed中心。第6卷，第11号，2015年10月二进制实数编码遗传算法基于K-均值聚类的机组组合问题麦A.法拉格，MA埃尔 -
Shorbagy，IM埃尔 -
Desoky，AA埃尔 -
SAWY，AA穆萨混沌同步在Lorenz系统阿尤布·汗，Prempal辛格不动点迭代法新的修改求解非线性方程组穆罕默德Saqib，穆罕默德·伊克巴尔，沙赫扎德艾哈迈德·沙希德·阿里，塔里克Ismaeel对于组合离散问题的全局优化的最新进展阿德尔R.阿瓦德，萨米亚O.尺半在AM特刊分形理论与应用（稿件截止时间：日）信息论（稿件截止时间：二零一五年十二月三十日）模糊数学及其应用（稿件截止时间：日）&&更多
看不懂，没帮上
登录百度帐号推荐应用
为兴趣而生，贴吧更懂你。或